|
|
|
|
|
|
|
M Tue W Th F |
|
28 July, 2026 |
|
|
sponsored by
|
|
|
|
Cambrex Advances US and European Expansions
|
| Cambrex continues to expand its facilities across the United States and Europe, including a $120 million investment in API manufacturing capabilities in Charles City, Iowa, and a $30 million investment in analytical development and process R&D in Milan, Italy. |
|
|
|
|
|
|
|
|
|
|
|
|
|
Alnylam’s stock has lost 30% of its value this year, despite a successful drug launch and accurate sales predictions. Max Gelman unpacks the reasons behind this falloff and what the company is doing about it. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
|
|
|
by Max Gelman
|
Alnylam is one of biopharma’s biggest mysteries so far in 2026. The broader market is seeing a resurgence after years of a bearish environment. M&A... | |
|
|
|
|
|
|
by Max Bayer
|
FDA staff threw cold water on Replimune’s advanced melanoma drug ahead of a critical meeting with agency advisors, writing that the pivotal study design failed... | |
|
|
|
|
|
 |
|
|
|
by Ayisha Sharma
|
Just a little over six months into his tenure as CEO at GSK, Luke Miels is making his mark. The UK pharma on Tuesday outlined... | |
|
|
|
|
|
|
by Kyle LaHucik
|
Claris Bio has a fresh CEO, new board chair and $118 million for two pivotal trials to see if its eye drop can succeed in a... | |
|
|
|
|
|
